Research · Sep 3, 2026
[GH] Guardant Health Thesis 2026: Shield CRC Screening Drives Liquid Biopsy Cycle
Guardant Health, Inc. (NASDAQ: GH) FY2025 revenue ~$830-880M (+25-32%) with adj. EPS ~-$3.20 to -$3.55 (continued opex investment + Shield commercial scale-up loss) reflecting continued post-2024 ~$520-555M aggregate Oncology revenue (~63% aggregate revenue mix; selected primary Guardant360 + Reveal MRD/recurrence) + selected continued post-2024 ~$200-225M aggregate Biopharma revenue (~24% aggregate revenue mix) + selected continued post-2024 ~$110-130M aggregate Screening (Shield) revenue (~13% aggregate revenue mix; selected primary post-July 2024 FDA approval) under continued Co-Founders + Co-CEOs Helmy Eltoukhy, PhD + AmirAli Talasaz, PhD since 2012 (~13-year tenure). US specialty cancer + liquid biopsy diagnostics company. Founded 2012 by Helmy Eltoukhy + AmirAli Talasaz in Redwood City California (~13-year heritage; selected pioneer US comprehensive genomic profiling liquid biopsy); selected post-2018 NASDAQ IPO; selected post-2018-2025 ~$2B+ cumulative equity capital; selected post-July 2024 FDA approval (Shield CRC screening); selected post-November 2024 Medicare ADLT $920/test Shield pricing. Headquartered in Redwood City California + Palo Alto California; ~1,800-2,000+ employees globally with ~$830-880M revenue. Three primary business segments: Oncology (~63% ~$520-555M), Biopharma (~24% ~$200-225M), Screening Shield (~13% ~$110-130M). Geographic mix: US ~95%+ + selected various international ~5%. Oncology liquid biopsy cycle (Guardant360 + Reveal): ~$520-555M Oncology revenue; ~225,000-245,000 aggregate annual Oncology tests; ~$2,500-2,800 aggregate Net Sales/test; ~50%+ aggregate US comprehensive genomic profiling liquid biopsy market share. Shield CRC screening launch: ~$110-130M Shield revenue; selected post-July 2024 FDA approval; selected post-November 2024 Medicare ADLT $920/test pricing; ~80-90% aggregate sensitivity stage I-III CRC; ~150M+ aggregate eligible US screening population. Co-Founders + Co-CEOs Helmy Eltoukhy + AmirAli Talasaz since 2012 (~13-year tenure); CFO Mike Bell. Capital position: ~$0.95-1.05B aggregate cash + investments balance; ~$110-150M aggregate quarterly cash burn; selected projected post-2027 cash flow break-even; ~125-130M diluted shares; no dividend (~$0 dividend track post-2018 IPO). FY2026 thesis: Shield CRC screening launch acceleration + Oncology + Reveal MRD growth + selected projected post-2027 cash flow break-even + selected Co-Founder ownership concentration. Risks: Natera + Exact Sciences + Foundation Medicine + Tempus AI + Caris Life Sciences + Cologuard Plus competition, payer access + Medicare reimbursement, sustained cash burn delay break-even.